Search

Your search keyword '"Khachatryan, Naira"' showing total 18 results
Start Over Author "Khachatryan, Naira" Search Limiters Full Text Publication Year Range Last 50 years
18 results on '"Khachatryan, Naira"'

2. Availability and costs of medicines for the treatment of tuberculosis in Europe

Author

Hasan Hafizi, Khachatryan, Naira, Aroyan, Harut, Kabasakalyan, Eduard, Knappik, Michael, Skrahina, Alena, Klimuk, Dzmitry, Nikolenka, Alena, Muylle, Inge, Milanov, Vladimir, Velkovska, Desislava, Tarinska, Neli, Bachiyska, Elizabeta, Jankovic, Mateja, Pieridou, Despo, Adamide, Tonia, Nicolaou, Nicos, Vasakova, Martina, Sukholytka, Mariia, Kopeckà, Emilia, Folkvardsen, Dorte Bek, Svensson, Erik, Danilovits, Manfred, Kummik, Tiina, Vasankari, Tuula, Fréchet-Jachym, Mathilde, Nahmiash, Audrey, Togonidze, Tamar, Avaliani, Zaza, Kinkladze, Inga, Aspindzelashvili, Rusudan, Bichashvili, Teona, Losaberidze, Gulnazi, Merabishvili, Tsitsino, Kalsdorf, Barbara, Manika, Katerina, Tsiakitzis, Karyofyllis, Bakos, Agnes, Ægisdóttir, Tinna Rán, Michelsen, Guðrún Svanhvít, Karlsdóttir, Kristín, McLaughlin, Anne-Marie, Fitzgibbon, Margaret, Chemtob, Daniel, Codecasa, Luigi R., Ferrarese, Maurizio, Torri, Stefania, Gjocaj, Majlinda, Kuksa, Liga, Davidaviciene, Edita, Wirtz, Gil, Perrin, Monique, Asciak, Analita Pace, Chesov, Dumitri, de Lange, Wiel, Akkerman, Onno, Poposka, Biljana Ilievska, Mack, Ulrich, Jensenius, Mogens, Kvalvik, Lajla, Mengshoel, Anne Torunn, Kruczak, Katarzyna, Duarte, Raquel, Ribeiro, Nadine, Ibraim, Elmira, Kaluzhenina, Anna, Barkanova, Olga, Pesut, Dragica, Solovic, Ivan, Svetina, Petra, Souza-Galvão, Maria-Luiza de, Millet, Joan-Pau, Casas, Xavi, Vives, Montserrat, Bruchfeld, Judith, Dalemo, Paulina, Jonsson, Jerker, Aeschbacher, Katrin, Keller, Peter, Özkara, Seref, Tiberi, Simon, Chen, Christabelle, Terleeva, Yana, Dudnyk, Andrii, Günther, Gunar, Guglielmetti, Lorenzo, Leu, Claude, Lange, Christoph, and van Leth, Frank

Published
2023
Full Text
View/download PDF

3. Availability of drugs and resistance testing for BPaLM regimen for rifampicin-resistant tuberculosis in Europe

Author

Günther, Gunar, primary, Guglielmetti, Lorenzo, additional, Kherabi, Yousra, additional, Duarte, Raquel, additional, Lange, Christoph, additional, Adamides, Tonia, additional, Akkerman, Onno, additional, Andersen, Aase Bengaard, additional, Bakos, Ágnes, additional, Bjarnason, Agnar, additional, Bruchfeld, Judith, additional, Chesov, Dumitru, additional, Codecasa, Luigi Ruffo, additional, Cirillo, Daniela, additional, Danilovits, Manfred, additional, Davidavičienė, Edita, additional, De Souza Galvão, Maria Luiza, additional, Garnier, Sandrine, additional, Gjocaj, Majlinda, additional, Günther, Gunar, additional, Ibraim, Elmira, additional, Kappnik, Michael, additional, Khachatryan, Naira, additional, Klimuk, Dzmitry, additional, Kuksa, Liga, additional, Jachym, Mathilde Frechet, additional, Josefsdottir, Kamilla, additional, Kaluzhenina, Anna, additional, Mack, Ulrich, additional, Makek, Mateja Jankovic, additional, Manika, Katerina, additional, Mclaughlin, Anne- Marie, additional, Mema, Donika, additional, Mengshoel, Anne Torunn, additional, Muylle, Inge, additional, Nanovic, Zorica, additional, Özkara, Şeref, additional, Perl, Sivan, additional, Pesut, Dragica, additional, Pierdou, Despo, additional, Ryskulov, Galym, additional, Skowroński, Marcin, additional, Solovic, Ivan, additional, Sukholytka, Mariia, additional, Svetina, Petra, additional, Terleeva, Yana, additional, Tiberi, Simon, additional, Togonidze, Tamara, additional, Torri, Stefania, additional, Turaev, Laziz, additional, Usmanova, Ruzilya, additional, Wirtz, Gil, additional, Vasankari, Tuula, additional, and Zhdanova, Elena, additional

Published
2024
Full Text
View/download PDF

4. Rate and Pattern of Rim Area Loss in Healthy and Progressing Glaucoma Eyes

Author

Hammel, Na'ama, Belghith, Akram, Bowd, Christopher, Medeiros, Felipe A, Sharpsten, Lucie, Mendoza, Nadia, Tatham, Andrew J, Khachatryan, Naira, Liebmann, Jeffrey M, Girkin, Christopher A, Weinreb, Robert N, and Zangwill, Linda M

Subjects
Biomedical and Clinical Sciences, Ophthalmology and Optometry, Aging, Neurodegenerative, Clinical Research, Eye Disease and Disorders of Vision, Adult, Aged, Aged, 80 and over, Black People, Disease Progression, Female, Follow-Up Studies, Glaucoma, Open-Angle, Healthy Volunteers, Humans, Intraocular Pressure, Male, Middle Aged, Ophthalmoscopy, Optic Disk, Optic Nerve Diseases, Prospective Studies, Scotoma, Tonometry, Ocular, Visual Field Tests, Visual Fields, White People, Young Adult, Clinical Sciences, Opthalmology and Optometry, Public Health and Health Services, Ophthalmology & Optometry, Ophthalmology and optometry
Abstract

PurposeTo characterize the rate and pattern of age-related and glaucomatous neuroretinal rim area changes in subjects of African and European descent.DesignProspective longitudinal study.ParticipantsTwo hundred ninety-six eyes of 157 healthy subjects (88 patients of African descent and 69 of European descent) and 73 progressing glaucoma eyes of 67 subjects (24 patients of African descent and 43 of European descent) from the Diagnostic Innovations in Glaucoma Study and the African Descent and Glaucoma Evaluation Study were included.MethodsGlobal and sectoral rim areas were measured using confocal laser scanning ophthalmoscopy. Masked stereophotograph review determined progression of glaucomatous optic disc damage. The rates of absolute rim area loss and percentage rim area loss in healthy and progressing glaucomatous eyes were compared using multivariate, nested, mixed-effects models.Main outcome measuresRate of rim area loss over time.ResultsThe median follow-up time was 5.0 years (interquartile range, 2.0-7.4 years) for healthy eyes and 8.3 years (interquartile range, 7.5-9.9 years) for progressing glaucoma eyes. The mean rate of global rim area loss was significantly faster in progressing glaucomatous eyes compared with healthy eyes for both rim area loss (-10.2×10(-3) vs. -2.8×10(-3) mm(2)/year, respectively; P < 0.001) and percentage rim area loss (-1.1% vs. -0.2%/year, respectively; P < 0.001), but considerable overlap existed between the 2 groups. Sixty-three percent of progressing glaucoma eyes had a rate of change faster than the fifth quantile of healthy eyes. For both healthy and progressing eyes, the pattern of rim area loss and percentage rim area loss were similar, tending to be fastest in the superior temporal and inferior temporal sectors. The rate of change was similar in progressing eyes of patients of African or European descent.ConclusionsCompared with healthy eyes, the mean rate of global rim area loss was 3.7 times faster and the mean rate of global percentage rim area loss was 5.4 times faster in progressing glaucoma eyes. A reference database of healthy eyes can be used to help clinicians distinguish age-related rim area loss from rim area loss resulting from glaucoma.

Published
2016

5. Diagnostic Accuracy of the Spectralis and Cirrus Reference Databases in Differentiating between Healthy and Early Glaucoma Eyes

Author

Silverman, Anna L, Hammel, Naama, Khachatryan, Naira, Sharpsten, Lucie, Medeiros, Felipe A, Girkin, Christopher A, Liebmann, Jeffrey M, Weinreb, Robert N, and Zangwill, Linda M

Subjects
Biomedical and Clinical Sciences, Ophthalmology and Optometry, Neurosciences, Eye Disease and Disorders of Vision, Clinical Research, Aging, Neurodegenerative, 4.2 Evaluation of markers and technologies, Detection, screening and diagnosis, Eye, Black or African American, Aged, Databases, Factual, Early Diagnosis, Gonioscopy, Healthy Volunteers, Humans, Middle Aged, Nerve Fibers, Ocular Hypertension, Reproducibility of Results, Retinal Ganglion Cells, Sensitivity and Specificity, Tomography, Optical Coherence, Vision Disorders, Visual Field Tests, Visual Fields, Clinical Sciences, Opthalmology and Optometry, Public Health and Health Services, Ophthalmology & Optometry, Ophthalmology and optometry
Abstract

PurposeTo evaluate and compare the diagnostic accuracy of global and sector analyses for detection of early visual field (VF) damage using the retinal nerve fiber layer (RNFL) reference databases of the Spectralis (Heidelberg Engineering, Heidelberg, Germany) and Cirrus (Carl Zeiss Meditec, Dublin, CA) spectral-domain optical coherence tomography (SD OCT) devices.MethodsHealthy subjects and glaucoma suspects from the Diagnostic Innovations in Glaucoma Study (DIGS) and African Descent and Glaucoma Evaluation Study (ADAGES) with at least 2 years of follow-up were included. Global and sectoral RNFL measures were classified as within normal limits, borderline (BL), and outside normal limits (ONL) on the basis of the device reference databases. The sensitivity of ONL classification was estimated in glaucoma suspect eyes that developed repeatable VF damage.ResultsA total of 353 glaucoma suspect eyes and 279 healthy eyes were included. A total of 34 (9.6%) of the glaucoma suspect eyes developed VF damage. In glaucoma suspect eyes, Spectralis and Cirrus ONL classification was present in 47 eyes (13.3%) and 24 eyes (6.8%), respectively. The sensitivity of the global RNFL ONL classification among eyes that developed VF damage was 23.5% for Cirrus and 32.4% for Spectralis. The specificity of within-normal-limits global classification in healthy eyes was 100% for Cirrus and 99.6% for Spectralis. There was moderate to substantial agreement between Cirrus and Spectralis classification as ONL.ConclusionsThe Spectralis and Cirrus reference databases have a high specificity for identifying healthy eyes and good agreement for detection of eyes with early glaucoma damage.

Published
2016

7. The African Descent and Glaucoma Evaluation Study (ADAGES): Predictors of Visual Field Damage in Glaucoma Suspects

Author

Khachatryan, Naira, Medeiros, Felipe A, Sharpsten, Lucie, Bowd, Christopher, Sample, Pamela A, Liebmann, Jeffrey M, Girkin, Christopher A, Weinreb, Robert N, Miki, Atsuya, Hammel, Na'ama, and Zangwill, Linda M

Subjects
Biomedical and Clinical Sciences, Ophthalmology and Optometry, Aging, Clinical Research, Eye Disease and Disorders of Vision, Adult, Black or African American, Aged, Blood Pressure, Cohort Studies, Female, Follow-Up Studies, Glaucoma, Open-Angle, Humans, Intraocular Pressure, Male, Middle Aged, Ocular Hypertension, Optic Disk, Optic Nerve Diseases, Proportional Hazards Models, Prospective Studies, Risk Factors, Tonometry, Ocular, Vision Disorders, Visual Acuity, Visual Field Tests, Visual Fields, White People, Clinical Sciences, Opthalmology and Optometry, Public Health and Health Services, Ophthalmology & Optometry, Ophthalmology and optometry
Abstract

PurposeTo evaluate racial differences in the development of visual field (VF) damage in glaucoma suspects.DesignProspective, observational cohort study.MethodsSix hundred thirty-six eyes from 357 glaucoma suspects with normal VF at baseline were included from the multicenter African Descent and Glaucoma Evaluation Study (ADAGES). Racial differences in the development of VF damage were examined using multivariable Cox proportional hazard models.ResultsThirty one of 122 African-descent participants (25.4%) and 47 of 235 European-descent participants (20.0%) developed VF damage (P = .078). In multivariable analysis, worse baseline VF mean deviation, higher mean arterial pressure during follow-up, and a race ∗ mean intraocular pressure (IOP) interaction term were significantly associated with the development of VF damage, suggesting that racial differences in the risk of VF damage varied by IOP. At higher mean IOP levels, race was predictive of the development of VF damage even after adjusting for potentially confounding factors. At mean IOPs during follow-up of 22, 24, and 26 mm Hg, multivariable hazard ratios (95% confidence intervals) for the development of VF damage in African-descent compared to European-descent subjects were 2.03 (1.15-3.57), 2.71 (1.39-5.29), and 3.61 (1.61-8.08), respectively. However, at lower mean IOP levels (below 22 mm Hg) during follow-up, African descent was not predictive of the development of VF damage.ConclusionIn this cohort of glaucoma suspects with similar access to treatment, multivariate analysis revealed that at higher mean IOP during follow-up, individuals of African descent were more likely to develop VF damage than individuals of European descent.

Published
2015

8. Rates of Retinal Nerve Fiber Layer Thinning in Glaucoma Suspect Eyes

Author

Miki, Atsuya, Medeiros, Felipe A, Weinreb, Robert N, Jain, Sonia, He, Feng, Sharpsten, Lucie, Khachatryan, Naira, Hammel, Na'ama, Liebmann, Jeffrey M, Girkin, Christopher A, Sample, Pamela A, and Zangwill, Linda M

Subjects
Biomedical and Clinical Sciences, Ophthalmology and Optometry, Neurosciences, Eye Disease and Disorders of Vision, Neurodegenerative, Clinical Research, Aging, Bioengineering, Detection, screening and diagnosis, 4.1 Discovery and preclinical testing of markers and technologies, Eye, Black or African American, Aged, Cohort Studies, Female, Humans, Intraocular Pressure, Male, Middle Aged, Nerve Fibers, Ocular Hypertension, Optic Disk, Prospective Studies, Retinal Ganglion Cells, Tomography, Optical Coherence, Vision Disorders, Visual Acuity, Visual Fields, White People, Clinical Sciences, Opthalmology and Optometry, Public Health and Health Services, Ophthalmology & Optometry, Ophthalmology and optometry
Abstract

PurposeTo compare the rates of retinal nerve fiber layer (RNFL) loss in patients suspected of having glaucoma who developed visual field damage (VFD) with those who did not develop VFD and to determine whether the rate of RNFL loss can be used to predict the development of VFD.DesignProspective, observational cohort study.ParticipantsGlaucoma suspects, defined as having glaucomatous optic neuropathy or ocular hypertension (intraocular pressure, >21 mmHg) without repeatable VFD at baseline, from the Diagnostic Innovations in Glaucoma Study and the African Descent and Glaucoma Evaluation Study.MethodsGlobal and quadrant RNFL thickness (RNFLT) were measured with the Spectralis spectral-domain optical coherence tomography (SD-OCT; Spectralis HRA+OCT [Heidelberg Engineering, Heidelberg, Germany]). Visual field damage was defined as having 3 consecutive abnormal visual fields. The rate of RNFL loss in eyes developing VFD was compared to eyes not developing VFD using multivariate linear mixed-effects models. A joint longitudinal survival model used the estimated RNFLT slope to predict the risk of developing VFD, while adjusting for potential confounding variables.Main outcome measuresThe rate of RNFL thinning and the probability of developing VFD.ResultsFour hundred fifty-four eyes of 294 glaucoma suspects were included. The average number of SD-OCT examinations was 4.6 (range, 2-9), with median follow-up of 2.2 years (0.4-4.1 years). Forty eyes (8.8%) developed VFD. The estimated mean rate of global RNFL loss was significantly faster in eyes that developed VFD compared with eyes that did not develop VFD (-2.02 μm/year vs. -0.82 μm/year; P

Published
2014

9. Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis

Author

Mbuagbaw, Lawrence, Guglielmetti, Lorenzo, Hewison, Catherine, Bakare, Nyasha, Bastard, Mathieu, Caumes, Eric, Frechet-Jachym, Mathilde, Robert, Jerome, Veziris, Nicolas, Khachatryan, Naira, Kotrikadze, Tinatin, Hayrapetyan, Armen, Avaliani, Zaza, Schunemann, Holger J., and Lienhardt, Christian

Subjects
Mortality -- Canada -- Armenia -- South Africa -- France, Microbial drug resistance -- Patient outcomes -- Care and treatment, Tuberculosis -- Patient outcomes -- Care and treatment, Death, Drug resistance, Public health, Health, World Health Organization
Abstract

In 2017, there were [approximately equal to] 10 million (range, 9.0-11.1 million) new cases of tuberculosis (TB) worldwide, of which [approximately equal to] 558,000 were rifampin-resistant TB (RR TB) or [...]

Published
2019
Full Text
View/download PDF

11. Availability and costs of medicines for the treatment of tuberculosis in Europe

Author

Günther, Gunar, Guglielmetti, Lorenzo, Leu, Claude, Lange, Christoph, van Leth, Frank, Hafizi, Hasan, Khachatryan, Naira, Aroyan, Harut, Kabasakalyan, Eduard, Knappik, Michael, Skrahina, Alena, Klimuk, Dzmitry, Nikolenka, Alena, Muylle, Inge, Milanov, Vladimir, Velkovska, Desislava, Tarinska, Neli, Bachiyska, Elizabeta, Jankovic, Mateja, Pieridou, Despo, Adamide, Tonia, Nicolaou, Nicos, Vasakova, Martina, Sukholytka, Mariia, Kopeckà, Emilia, Andersen, Åse Bengård, Folkvardsen, Dorte Bek, Svensson, Erik, Danilovits, Manfred, Kummik, Tiina, Vasankari, Tuula, Fréchet-Jachym, Mathilde, Nahmiash, Audrey, Togonidze, Tamar, Avaliani, Zaza, Kinkladze, Inga, Aspindzelashvili, Rusudan, Bichashvili, Teona, Losaberidze, Gulnazi, Merabishvili, Tsitsino, Kalsdorf, Barbara, Manika, Katerina, Tsiakitzis, Karyofyllis, Bakos, Agnes, Ægisdóttir, Tinna Rán, Michelsen, Guðrún Svanhvít, Karlsdóttir, Kristín, McLaughlin, Anne-Marie, Fitzgibbon, Margaret, Chemtob, Daniel, Codecasa, Luigi R., Ferrarese, Maurizio, Torri, Stefania, Gjocaj, Majlinda, Kuksa, Liga, Davidaviciene, Edita, Wirtz, Gil, Perrin, Monique, Asciak, Analita Pace, Chesov, Dumitri, de Lange, Wiel, Akkerman, Onno, Poposka, Biljana Ilievska, Mack, Ulrich, Jensenius, Mogens, Kvalvik, Lajla, Mengshoel, Anne Torunn, Kruczak, Katarzyna, Duarte, Raquel, Ribeiro, Nadine, Ibraim, Elmira, Kaluzhenina, Anna, Barkanova, Olga, Pesut, Dragica, Solovic, Ivan, Svetina, Petra, Souza-Galvão, Maria-Luiza de, Millet, Joan-Pau, Casas, Xavi, Vives, Montserrat, Bruchfeld, Judith, Dalemo, Paulina, Jonsson, Jerker, Aeschbacher, Katrin, Keller, Peter, Özkara, Seref, Tiberi, Simon, Chen, Christabelle, Terleeva, Yana, Dudnyk, Andrii, Health Economics and Health Technology Assessment, APH - Global Health, APH - Methodology, and Microbes in Health and Disease (MHD)

Subjects
Microbiology (medical), Evropa, Extensively Drug-Resistant Tuberculosis, Antitubercular Agents, Capacity building, 610 Medicine & health, MDR-TB, Mycobacterium tuberculosis - terapija z zdravili, Microbial Sensitivity Tests, Antimicrobial resistance, Medicines, Mycobacterium tuberculosis - drug therapy, SDG 3 - Good Health and Well-being, Tuberculosis, Multidrug-Resistant, Humans, Tuberculosis, tuberkuloza - terapija z zdravili, health care costs - drug therapy, Mycobacterium tuberculosis, General Medicine, END-TB strategy, udc:616-002, tuberculosis - drug therapy, Costs, stroški zdravstvene oskrbe - terapija z zdravili, Europe, Infectious Diseases, Availability of medicines
Abstract

Objectives: To evaluate the access to comprehensive diagnostics and novel antituberculosis medicines in European countries.Methods: We investigated the access to genotypic and phenotypic Mycobacterium tuberculosis drug susceptibility testing and the availability of antituberculosis drugs and calculated the cost of drugs and treatment regimens at major tuberculosis treatment centres in countries of the WHO European region where rates of drug-resistant tuberculosis are the highest among all WHO regions. Results were stratified by middle-income and high-income countries.Results: Overall, 43 treatment centres from 43 countries participated in the study. For WHO group A drugs, the frequency of countries with the availability of phenotypic drug susceptibility testing was as follows: (a) 75% (30/40) for levofloxacin, (b) 82% (33/40) for moxifloxacin, (c) 48% (19/40) for bedaquiline, and (d) 72% (29/40) for linezolid. Overall, of the 43 countries, 36 (84%) and 24 (56%) countries had access to bedaquiline and delamanid, respectively, whereas only 6 (14%) countries had access to rifapentine. The treatment of patients with extensively drug-resistant tuberculosis with a regimen including a carbapenem was available only in 17 (40%) of the 43 countries. The median cost of regimens for drug-susceptible tuberculosis, multidrug-resistant/rifampicin-resistant tuberculosis (shorter regimen, including bedaquiline for 6 months), and extensively drug-resistant tuberculosis (including bedaquiline, delamanid, and a carbapenem) were €44 (minimum–maximum, €15–152), €764 (minimum–maximum, €542–15152), and €8709 (minimum–maximum, €7965–11759) in middle-income countries (n = 12) and €280 (minimum–maximum, €78–1084), €29765 (minimum–maximum, €11116–40584), and €217591 (minimum–maximum, €82827–320146) in high-income countries (n = 29), respectively.Discussion: In countries of the WHO European region, there is a widespread lack of drug susceptibility testing capacity to new and repurposed antituberculosis drugs, lack of access to essential medications in several countries, and a high cost for the treatment of drug-resistant tuberculosis.

Published
2023

12. Grand Challenges in global eye health: a global prioritisation process using Delphi method

Author

Ramke, Jacqueline, primary, Evans, Jennifer R, additional, Habtamu, Esmael, additional, Mwangi, Nyawira, additional, Silva, Juan Carlos, additional, Swenor, Bonnielin K, additional, Congdon, Nathan, additional, Faal, Hannah B, additional, Foster, Allen, additional, Friedman, David S, additional, Gichuhi, Stephen, additional, Jonas, Jost B, additional, Khaw, Peng T, additional, Kyari, Fatima, additional, Murthy, Gudlavalleti V S, additional, Wang, Ningli, additional, Wong, Tien Y, additional, Wormald, Richard, additional, Yusufu, Mayinuer, additional, Taylor, Hugh, additional, Resnikoff, Serge, additional, West, Sheila K, additional, Burton, Matthew J, additional, Aghaji, Ada, additional, Adewole, Adeyemi T, additional, Csutak, Adrienne, additional, Salam, Ahmad Shah, additional, Paduca, Ala, additional, Bron, Alain M, additional, Denniston, Alastair K, additional, Lazo Legua, Alberto, additional, Halim, Aldiana, additional, Tefera, Alemayehu Woldeyes, additional, Mwangi, Alice, additional, Jenkins, Alicia J, additional, Davis, Amanda, additional, Meddeb-Ouertani, Amel, additional, Wali, Amina H, additional, Palis, Ana G, additional, Bastos de Carvalho, Ana, additional, Joshi, Anagha, additional, Kreis, Andreas J, additional, Mueller, Andreas, additional, Bastawrous, Andrew, additional, Cooper, Andrew, additional, Smith, Andrew F, additional, Grzybowski, Andrzej, additional, Arvind, Anitha, additional, Karanu, Anne M, additional, Orlina, Anne O, additional, Burnett, Anthea, additional, Yashadhana, Aryati, additional, Abeydeera, Asela P, additional, Abdurakhmanova, Aselia, additional, Mohamed, Ashik, additional, Bacchav, Ashish, additional, Bernhisel, Ashlie, additional, Webson, Aubrey Walton, additional, Azuara-Blanco, Augusto, additional, Hossain, Ava, additional, Ilhan, Bayazit, additional, Assumpta Lucienne, Bella, additional, Tousignant, Benoit, additional, Shamanna, Bindiganavale R, additional, Wiafe, Boateng, additional, Mueller, Brigitte, additional, Caglar, Cagatay, additional, Mpyet, Caleb, additional, Abraham, Carl H, additional, Cheung, Carol Y, additional, Thiel, Cassandra L, additional, Jan, Catherine L, additional, Emedike, Chike, additional, Chuluunkhuu, Chimgee, additional, Chinyere, Chinomso, additional, Henein, Christin, additional, Gilbert, Clare E, additional, Bascaran, Covadonga, additional, Nitulescu, Cristina Elena, additional, Patel, Daksha, additional, Bachani, Damodar, additional, Kiage, Daniel, additional, Etya'ale, Daniel, additional, Dahdal, David, additional, Woo Lawson, Dawn, additional, Godin, Denise, additional, Nkanga, Dennis G, additional, Ondeyo, Dennis M, additional, O'Brien, Donna, additional, Mutie, Dorothy M, additional, Alalawi, Ebtisam S K, additional, Mayorga, Eduardo, additional, Bin Hashim, Effendy, additional, Ashrafi, Elham, additional, Kishiki, Elizabeth Andrew, additional, Kurian, Elizabeth, additional, D'Esposito, Fabrizio, additional, Masila, Faith, additional, Pena, Fernando Yaacov, additional, Büsch, Fortunat, additional, Topouzis, Fotis, additional, Bandello, Francesco, additional, Oyediji, Funmilayo J, additional, Thumann, Gabriele, additional, Ezz Elarab, Gamal, additional, Kitema, Gatera Fiston, additional, Schlenther, Gerhard, additional, Fefoame, Gertrude Oforiwa, additional, Cochrane, Gillian M, additional, Laganovska, Guna, additional, Awan, Haroon R, additional, Ansari, Harris M, additional, Philippin, Heiko, additional, Burn, Helen, additional, Dimaras, Helen, additional, Filipe, Helena P, additional, Monye, Henrietta I, additional, Kandel, Himal, additional, Randrianarisoa, Hoby Lalaina, additional, Jones, Iain, additional, Murdoch, Ian E, additional, Fabian, Ido Didi, additional, Khan, Imran A, additional, Sharma, Indra P, additional, Elbeih, Islam, additional, Mactaggart, Islay, additional, Pastor, J Carlos, additional, Keunen, Jan E E, additional, Ohuma, Jane A, additional, Pithuwa Nirwoth, Jason, additional, Hammou, Jaouad, additional, Vianna, Jayme R, additional, Biao, Jean-eudes, additional, Burr, Jennifer M, additional, Keenan, Jeremy D, additional, Blijkers, Jess, additional, Black, Joanna M, additional, Barbosa Breda, Joao, additional, Furtado, Joao M, additional, Buchan, John C, additional, Lawrenson, John G, additional, Kempen, John H, additional, Ehrlich, Joshua R, additional, Stern, Judith, additional, Zhang, Justine H, additional, Keskinbora, Kadircan H, additional, Knoll, Karin M, additional, Blanchet, Karl, additional, Schmid, Katrina L, additional, Ono, Koichi, additional, Ogundimu, Kolawole, additional, Balo, Komi, additional, Somda, Kussome Paulin, additional, Yeboah, Kwame, additional, Amissah-Arthur, Kwesi N, additional, Nasehi, Leone, additional, Øverland, Lene, additional, Vijaya, Lingam, additional, Keay, Lisa, additional, Hamm, Lisa M, additional, Mowatt, Lizette, additional, Harrison-Williams, Lloyd C M, additional, Silva, Lucia, additional, Bilotto, Luigi, additional, Mörchen, Manfred, additional, Rabiu, Mansur, additional, Zondervan, Marcia, additional, Chagunda, Margarida, additional, Sandinha, Maria Teresa, additional, Yee Melgar, Mariano, additional, Salas Vargas, Marisela, additional, Daniell, Mark D, additional, Katibeh, Marzieh, additional, Broom, Matt, additional, Collins, Megan E, additional, Alp, Mehmet Numan, additional, Kwarteng, Michael A, additional, Belkin, Michael, additional, Gichangi, Michael, additional, Sylvanowicz, Michelle, additional, Wu, Min, additional, Cano, Miriam R, additional, Shalaby, Mohammad, additional, Duggal, Mona, additional, Khairallah, Moncef, additional, Batur, Muhammed, additional, Bikbov, Mukharram M, additional, Ramappa, Muralidhar, additional, Pamarathi, Nagaraju, additional, Khachatryan, Naira, additional, Muhammad, Nasiru, additional, Kennedy, Neil, additional, Murray, Neil, additional, Beare, Nicholas A V, additional, Astbury, Nick, additional, Carnt, Nicole A, additional, St Rose, Nigel A, additional, Barker, Nigel H, additional, Pehere, Niranjan K, additional, Uche, Nkechinyere J, additional, Lois, Noemi, additional, Awe, Oluwaseun O, additional, Mujica, Oscar J, additional, Okolo, Oteri E, additional, Rani, Padmaja Kumari, additional, Ruamviboonsuk, Paisan, additional, Ndiaye, Papa Amadou, additional, Dhakhwa, Parami, additional, Rozsival, Pavel, additional, Mbulawa, Pearl K, additional, Keane, Pearse A, additional, Jones, Pete R, additional, Holland, Peter, additional, Nukella, Phanindra Babu, additional, Burgess, Philip I, additional, O'Dwyer, Pinar Aydin, additional, Piyasena, Prabhath, additional, Bastola, Pradeep, additional, Morjaria, Priya, additional, Nasimee, Qais, additional, Rambacal, Raizza A T, additional, Das, Rajdeep, additional, Khandekar, Rajiv B, additional, Azad, Rajvardhan, additional, Bashshur, Ramona, additional, Sousa, Raúl A R C, additional, Oenga, Rebecca, additional, Gurung, Reeta, additional, Geneau, Robert, additional, Jacobs, Robert J, additional, Finger, Robert P, additional, Guymer, Robyn H, additional, Sevciuc, Rodica, additional, Khanna, Rohit C, additional, George, Ronnie, additional, Graham, Ronnie, additional, Kawasaki, Ryo, additional, Ho, S May, additional, Mishra, Sailesh Kumar, additional, Buttan, Sandeep, additional, Block, Sandra S, additional, Talero, Sandra, additional, Yoon, Sangchul, additional, Joseph, Sanil, additional, Safi, Sare, additional, Dodson, Sarity, additional, Munoz, Sergio R, additional, Bakayoko, Seydou, additional, Mohammadi, Seyed Farzad, additional, Muez, Shabir Ahmad, additional, Pardhan, Shahina, additional, Hopkins, Shelley, additional, Sheu, Shwu-Jiuan, additional, Coulibaly, Sidi Mohamed, additional, Schellini, Silvana A, additional, Arunga, Simon, additional, Bush, Simon R, additional, Sivaprasad, Sobha, additional, Salomao, Solange R, additional, Marmamula, Srinivas, additional, Onwubiko, Stella N, additional, Misra, Stuti L, additional, Kuyyadiyil, Subeesh, additional, Kulkarni, Sucheta, additional, khanal, Sudarshan, additional, Yasmin, Sumrana, additional, Pavljasevic, Suzana Nikolic, additional, Gilbert, Suzanne S, additional, Braithwaite, Tasanee, additional, Ghidirimschi, Tatiana, additional, Ravilla, Thulasiraj, additional, Fricke, Timothy R, additional, Cogliati, Tiziana, additional, Kassa, Tsehaynesh, additional, Peto, Tunde, additional, Dibb, Ute, additional, Lansingh, Van C, additional, Hu, Victor H, additional, Sheffield, Victoria M, additional, Mathenge, Wanjiku, additional, Dean, William H, additional, Nolan, Winifred, additional, Hiratsuka, Yoshimune, additional, Mahsood, Yousaf Jamal, additional, and Sapkota, Yuddha, additional

Published
2022
Full Text
View/download PDF

13. Concomitant Treatment of Chronic Hepatitis C With Direct-Acting Antivirals and Multidrug-Resistant Tuberculosis Is Effective and Safe

Author

Melikyan, Nara, primary, Huerga, Helena, additional, Atshemyan, Hakob, additional, Kirakosyan, Ohanna, additional, Sargsyants, Narina, additional, Aydinyan, Tsovinar, additional, Saribekyan, Nora, additional, Khachatryan, Naira, additional, Oganezova, Izabella, additional, Falcao, Joana, additional, Balkan, Suna, additional, and Hewison, Cathy, additional

Published
2021
Full Text
View/download PDF

14. Primary Open-Angle African American Glaucoma Genetics (POAAGG) Study: gender and risk of POAG in African Americans

Author

Khachatryan, Naira, primary, Pistilli, Maxwell, additional, Maguire, Maureen G., additional, Salowe, Rebecca J., additional, Fertig, Raymond M., additional, Moore, Tanisha, additional, Gudiseva, Harini V., additional, Chavali, Venkata R. M., additional, Collins, David W., additional, Daniel, Ebenezer, additional, Murphy, Windell, additional, Henderer, Jeffrey D., additional, Lehman, Amanda, additional, Cui, Qi, additional, Addis, Victoria, additional, Sankar, Prithvi S., additional, Miller-Ellis, Eydie G., additional, and O’Brien, Joan M., additional

Published
2019
Full Text
View/download PDF

16. Cost and yield considerations when expanding recruitment for genetic studies: the primary open-angle African American glaucoma genetics study

Author

Salowe, Rebecca, primary, O’Keefe, Laura, additional, Merriam, Sayaka, additional, Lee, Roy, additional, Khachatryan, Naira, additional, Sankar, Prithvi, additional, Miller-Ellis, Eydie, additional, Lehman, Amanda, additional, Addis, Victoria, additional, Murphy, Windell, additional, Henderer, Jeffrey, additional, Maguire, Maureen, additional, and O’Brien, Joan, additional

Published
2017
Full Text
View/download PDF

17. Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges

Author

Tadolini, Marina, primary, Garcia-Prats, Anthony J., additional, D'Ambrosio, Lia, additional, Hewison, Catherine, additional, Centis, Rosella, additional, Schaaf, H. Simon, additional, Marais, Ben J., additional, Ferreira, Hannetjie, additional, Caminero, Jose A., additional, Jonckheere, Sylvie, additional, Sinha, Animesh, additional, Herboczek, Krzysztof, additional, Khaidarkhanova, Zarema, additional, Hayrapetyan, Armen, additional, Khachatryan, Naira, additional, Urtkmelidze, Ia, additional, Loreti, Carolina, additional, Esposito, Susanna, additional, Matteelli, Alberto, additional, Furin, Jennifer, additional, Varaine, Francis, additional, and Migliori, Giovanni Battista, additional

Published
2016
Full Text
View/download PDF

18. Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges

Author

Rosella Centis, Jose A. Caminero, Alberto Matteelli, Naira Khachatryan, Animesh Sinha, Jennifer Furin, Sylvie Jonckheere, Anthony J. Garcia-Prats, Hannetjie Ferreira, Catherine Hewison, Zarema Khaidarkhanova, Giovanni Battista Migliori, Susanna Esposito, Armen Hayrapetyan, Ia Urtkmelidze, H. Simon Schaaf, Ben J. Marais, Marina Tadolini, Carolina V Loreti, Krzysztof Herboczek, Lia D'Ambrosio, Francis Varaine, Tadolini, Marina, Garcia-Prats, Anthony J., D'Ambrosio, Lia, Hewison, Catherine, Centis, Rosella, Schaaf, H. Simon, Marais, Ben J., Ferreira, Hannetjie, Caminero, Jose A., Jonckheere, Sylvie, Sinha, Animesh, Herboczek, Krzysztof, Khaidarkhanova, Zarema, Hayrapetyan, Armen, Khachatryan, Naira, Urtkmelidze, Ia, Loreti, Carolina, Esposito, Susanna, Matteelli, Alberto, Furin, Jennifer, Varaine, Franci, and Migliori, Giovanni Battista

Subjects
Compassionate Use Trials, Male, Pulmonary and Respiratory Medicine, medicine.medical_specialty, Pediatrics, Adolescent, Extensively Drug-Resistant Tuberculosis, Treatment outcome, Antitubercular Agents, Alternative medicine, 03 medical and health sciences, 0302 clinical medicine, medicine, Humans, 030212 general & internal medicine, Child, Intensive care medicine, Agora, business.industry, Compassionate Use, Extensively drug-resistant tuberculosis, medicine.disease, Research Letters, Multiple drug resistance, Treatment Outcome, 030228 respiratory system, Pulmonary and Respiratory Medicine, children, Female, business
Abstract

The World Health Organization (WHO) estimated that 480 000 new multidrug-resistant (MDR) tuberculosis (TB) cases occurred globally in 2014, with 190 000 deaths. Limited data are available on the burden of MDR-TB in children. A recent systematic review estimated that 32 000 children acquire MDR-TB annually; of these, very few are correctly diagnosed and provided with appropriate treatment [1]., First experience and challenges of compassionate use of new anti-TB drugs to treat MDR- and XDR-TB in children http://ow.ly/SWXF300a0UX

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results